Total Payments
$215,309
2024 Payments
$4,086
Companies
18
Transactions
154
Medicare Patients
590
Medicare Billing
$94,729
Payment Breakdown by Category
Consulting$124,450 (57.8%)
Other$34,442 (16.0%)
Education$24,028 (11.2%)
Research$18,518 (8.6%)
Travel$10,535 (4.9%)
Food & Beverage$3,336 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $124,450 | 38 | 57.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,642 | 14 | 12.4% |
| Education | $24,028 | 2 | 11.2% |
| Unspecified | $18,518 | 6 | 8.6% |
| Travel and Lodging | $10,535 | 41 | 4.9% |
| Honoraria | $6,800 | 2 | 3.2% |
| Food and Beverage | $3,336 | 50 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000 | 1 | 0.5% |
Payments by Type
General
$196,791
148 transactions
Research
$18,518
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $67,649 | 47 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $32,487 | 9 | $0 (2024) |
| Celgene Corporation | $26,631 | 12 | $0 (2023) |
| PFIZER INC. | $26,317 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $19,327 | 17 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $16,184 | 19 | $0 (2023) |
| AbbVie Inc. | $5,032 | 13 | $0 (2023) |
| Stemline Therapeutics Inc. | $4,835 | 3 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,422 | 4 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $3,190 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,086 | 2 | E.R. Squibb & Sons, L.L.C. ($2,686) |
| 2023 | $43,127 | 10 | E.R. Squibb & Sons, L.L.C. ($21,342) |
| 2022 | $24,357 | 19 | JAZZ PHARMACEUTICALS INC. ($8,280) |
| 2021 | $18,994 | 10 | Astellas Pharma US Inc ($7,533) |
| 2020 | $17,549 | 8 | Novartis Pharmaceuticals Corporation ($11,093) |
| 2019 | $30,290 | 32 | Novartis Pharmaceuticals Corporation ($10,456) |
| 2018 | $50,054 | 40 | Novartis Pharmaceuticals Corporation ($19,327) |
| 2017 | $26,853 | 33 | Novartis Pharmaceuticals Corporation ($14,663) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/22/2024 | E.R. Squibb & Sons, L.L.C. | — | Education | In-kind items and services | $2,686.00 | General |
| 02/01/2024 | PFIZER INC. | BOSULIF (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: BOSUTINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/28/2023 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,700.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/13/2023 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Education | In-kind items and services | $21,342.00 | General |
| Category: Oncology | ||||||
| 07/25/2023 | Celgene Corporation | ONUREG (Drug) | Consulting Fee | Cash or cash equivalent | $7,148.28 | General |
| Category: Oncology | ||||||
| 05/04/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | — | Cash or cash equivalent | $3,190.00 | Research |
| Study: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications • Category: Oncology | ||||||
| 02/26/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $46.15 | General |
| Category: BioOncology | ||||||
| 02/21/2023 | Celgene Corporation | ONUREG (Drug) | Consulting Fee | Cash or cash equivalent | $4,151.00 | General |
| Category: Oncology | ||||||
| 02/17/2023 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/03/2023 | Celgene Corporation | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,000.00 | General |
| 01/05/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 01/04/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/21/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $89.41 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/21/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,096.25 | General |
| 12/12/2022 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Oncology | ||||||
| 12/09/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $120.85 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2022 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $17.93 | General |
| 11/30/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/30/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/30/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/30/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/29/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $522.20 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/29/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $245.53 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $11,678 | 3 |
| A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications | Karyopharm Therapeutics Inc. | $3,190 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,250 | 1 |
| BOSUTINIB MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 80 | 137 | $27,529 | $12,235 |
| 2022 | 3 | 145 | 197 | $46,433 | $20,594 |
| 2021 | 4 | 176 | 335 | $64,919 | $31,500 |
| 2020 | 3 | 189 | 327 | $76,386 | $30,400 |
Total Patients
590
Total Services
996
Medicare Billing
$94,729
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 54 | 76 | $17,992 | $8,236 | 45.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 44 | $6,512 | $2,819 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 17 | $3,025 | $1,180 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 93 | 143 | $32,395 | $14,730 | 45.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $10,153 | $4,307 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 23 | $3,885 | $1,557 | 40.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 97 | 156 | $33,590 | $17,963 | 53.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 109 | $16,132 | $6,297 | 39.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 26 | 26 | $8,450 | $3,869 | 45.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 34 | 44 | $6,747 | $3,370 | 50.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 119 | 207 | $44,505 | $17,330 | 38.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 57 | 57 | $18,525 | $7,744 | 41.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 63 | $13,356 | $5,326 | 39.9% |
About Dr. Kendra Sweet, M.D
Dr. Kendra Sweet, M.D is a Hematology & Oncology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1609074574.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kendra Sweet, M.D has received a total of $215,309 in payments from pharmaceutical and medical device companies, with $4,086 received in 2024. These payments were reported across 154 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($124,450).
As a Medicare-enrolled provider, Sweet has provided services to 590 Medicare beneficiaries, totaling 996 services with total Medicare billing of $94,729. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tampa, FL
- Active Since 07/03/2007
- Last Updated 04/21/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1609074574
Products in Payments
- ONUREG (Drug) $34,717
- RYDAPT (Drug) $29,164
- VYXEOS (Drug) $16,167
- XOSPATA (Drug) $11,895
- BOSULIF (Drug) $11,282
- TASIGNA (Drug) $9,560
- MYLOTARG (Biological) $6,500
- SPRYCEL (Drug) $6,224
- Revlimid (Drug) $6,188
- ICLUSIG (Drug) $5,742
- KISQALI (Drug) $5,348
- Venclexta (Drug) $4,357
- XPOVIO (Drug) $3,190
- TIBSOVO (Drug) $3,069
- SCEMBLIX (Drug) $795.85
- VENCLEXTA (Drug) $675.00
- IMBRUVICA (Drug) $124.27
- BESPONSA (Biological) $92.07
- Venclexta (Biological) $46.15
- ELZONRIS (Drug) $35.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tampa
Damian Laber, Md, MD
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Eduardo Sotomayor, Md, MD
Hematology & Oncology — Payments: $447,992
Hematology & Oncology $447,992
Ariel Grajales-Cruz
Hematology & Oncology — Payments: $424,303
Hematology & Oncology $424,303
Khaldoun Almhanna, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $173,538
Hematology & Oncology $173,538
Hayder Saeed, M.d, M.D
Hematology & Oncology — Payments: $140,365
Hematology & Oncology $140,365
Dr. Hatem Soliman, Md, MD
Hematology & Oncology — Payments: $138,958
Hematology & Oncology $138,958